-

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Celsius Holdings, Inc. Investors (CELH)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of Florida on behalf of those who acquired Celsius Holdings, Inc. (“Celsius” or the “Company”) (NASDAQ:CELH) securities during the period of February 29, 2024, to September 4, 2024, inclusive (“the Class Period”). Investors have until January 21, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

The lawsuit alleges that on May 27, 2024, the price of Celsius stock declined materially as analysts and investors digested some of the latest retail store trends reported by Nielsen, a global data and analytics company. Morgan Stanley noted that Celsius’ sales growth slowed sequentially in weekly retail data – slowing to 39% year-over-year in the week ended May 18, 2024, down from 50% in the week ended May 4, 2024. Morgan Stanley warned that Celsius faced difficult sales comparisons over the next several quarters as it rolled over the anniversary of its Distribution Agreement with PepsiCo, Inc. (“Pepsi”). Similarly, Stifel warned that sales could be dramatically diminished as Pepsi reduced the amount of Celsius inventory it held. The price of Celsius shares declined by $12.23 per share, or approximately 13%, from $95.15 on May 24, 2024, to close at $82.92 on May 28, 2024.

Then, on September 4, 2024, Celsius’ CEO, John Fieldly presented at the Barclays 17th Annual Global Consumer Staples Conference. During the conference, Fieldly discussed the Company’s Distribution Agreement with Pepsi, and revealed that Celsius’ sales to Pepsi had decreased by “roughly around $100 million to $120 million … from what Pepsi ordered last quarter.” Fieldly added Celsius was “still seeing these inventory levels being reduced.” Additionally, it was noted that Celsius’ prior sales to Pepsi far outstripped market demand for Celsius products, and Pepsi was drawing down excess inventory from its warehouses. On this news, the price of Celsius shares declined by $4.25 per share, or approximately 12%, from $36.64 on September 3, 2024, to close at $32.39 on September 4, 2024.

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Celsius materially oversold inventory to Pepsi far in excess of demand, and faced a looming sales cliff during which Pepsi would significantly reduce its purchases of Celsius products; (2) as Pepsi drew down significant amounts of inventory overstock, Celsius sales would materially decline in future periods, hurting Celsius financial performance and outlook; (3) Celsius sales rate to Pepsi was unsustainable and created a misleading impression of Celsius financial performance and outlook; and (4) as a result, Celsius business metrics and financial prospects were not as strong as indicated in defendants Class Period statements.

If you purchased or otherwise acquired Celsius securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:CELH

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, V...

CRMT Investors: Contact Kirby McInerney LLP About Investigation into Car-Mart, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Car-Mart, Inc. (“Car-Mart” or the “Company”) (NASDAQ:CRMT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 15, 2025, Car-Mart disclosed it would delay filing its annual report because “management identified the need t...

INSP INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Inspire Medical Systems, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE:INSP) investors of the January 5, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Inspire securities between August 6, 2024 through August 4, 2025 (“the Class Period”). Follow the link below for more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit About? The lawsuit allege...
Back to Newsroom